Arthrex, Inc is developing heparin coated bone marrow harvest components with the intent to eliminate a aqueous heparin wash prior to marrow harvest. Bone marrow aspirate will then be transferred to the ACP Max System to concentrate MSCs and beneficial cytokines. The goal for testing is twofold: 1. to elucidate if clotting is reduced and maximize the amount of “unactivated” cells harvested (heparin coated compared to control/standard of care) and 2. to determine a centrifugation regime to maximize MSC yield in the ACP Max. Testing will include cell counts and smears of extracted BMA at time zero and 15 minutes post-harvest; cell counts of BMA and BMC from ACP Max; and cytokine ELISAs on BMA and BMC.